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rognostic Value of Plasma Erythropoietin
n Mortality in Patients With Chronic Heart Failure
eter van der Meer, MD,* Adriaan A. Voors, MD,* Erik Lipsic, MD,*† Tom D. J. Smilde, MD,*
iek H. van Gilst, PHD,† Dirk J. van Veldhuisen, MD, FACC*
roningen, the Netherlands
OBJECTIVES This study aimed to investigate the prognostic importance of plasma erythropoietin (EPO)
levels in chronic heart failure (CHF) patients.
BACKGROUND Anemia is common and is associated with an impaired survival in patients with CHF.
Erythropoietin is a hematopoietic growth factor, upregulated in anemic conditions. Little is
known about the pathophysiology of anemia in CHF and the prognostic importance of
plasma EPO levels in CHF patients.
METHODS In 74 patients with CHF (age, 61  2 years; left ventricular ejection fraction, 0.31  0.01;
peak oxygen consumption, 19.1  0.6 [mean  SEM]) and in 15 control patients,
hemoglobin levels and plasma concentrations of EPO and brain natriuretic peptide were
measured.
RESULTS During a mean follow-up of 3.0 years (range, 2.3 to 5.3 years), 22 patients (30%) died.
Anemia was present in 24% of the patients. Multivariate analysis showed that plasma EPO
(p 0.026) and hemoglobin levels (p 0.005) were independent predictors of survival in this
CHF population. We observed only a mild inverse correlation between the logarithm of EPO
and hemoglobin levels (r2  0.08, p  0.02) in CHF patients, whereas the control group
showed a clear significant inverse correlation (r2  0.44, p  0.007).
CONCLUSIONS Elevated plasma EPO levels are associated with an impaired prognosis independent of
hemoglobin levels and other established markers of CHF severity. Furthermore, in the CHF
patients, EPO levels poorly correlate with the hemoglobin levels, in contrast with the control
group. (J Am Coll Cardiol 2004;44:63–7) © 2004 by the American College of Cardiology
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ynemia is commonly observed in patients with chronic
eart failure (CHF) (1–3). One of the first studies
ublished on anemia and CHF showed in 142 patients
ith CHF that mean hemoglobin (Hb) concentration
ecreased from 13.7 g/dl in mild CHF to 10.9 g/dl in
evere CHF (4). Several other studies have also examined
he prognosis of anemia in patients with CHF (2,3).
emoglobin levels 12.3 g/dl are associated with wors-
ned symptoms and impaired survival. Although large
tudies have confirmed these finding, the origin of
nemia in CHF remains unclear (5).
In general, in response to anemia, the kidneys produce
rythropoietin (EPO), which in turn stimulates red blood
ell production (6,7). Previous studies already showed
hat patients with CHF exhibit elevated levels of EPO
8,9), although the significance of this finding has still to
e elucidated. In addition, EPO levels may be correlated
ith the severity of CHF (8). Therefore, we hypothesized
hat elevated EPO levels are associated with a poorer
rognosis. In the present study, we aimed to establish the
From the *Department of Cardiology, University Hospital Groningen, Groningen,
he Netherlands; and †Department of Clinical Pharmacology, University of
roningen, Groningen, the Netherlands. Dr. van der Meer is supported by NWO
onMW. Dr. Lipsic is supported by GUIDE. Dr. van Veldhuisen is an established
nvestigator of the Netherlands Heart Foundation (grant D97-017).
Manuscript received December 9, 2003; revised manuscript received February 20,f004, accepted March 16, 2004.rognostic value of both EPO and Hb on mortality in
HF patients.
ETHODS
atients. The prognostic values of EPO and Hb levels
ere retrospectively assessed in 74 Caucasian CHF patients
ith stable, mild-to-advanced CHF consecutively admitted
o our center (a tertiary referral center), between 1998 and
000. Referral of patients to our clinic was by general
ractitioners, cardiologists, local hospitals, or other units of
ur hospital. Patients were treated for heart failure at the
utpatient clinic. Patients were stable on medication for at
east three months. In all patients, CHF was diagnosed on
he basis of standard criteria, and presence of left ventricular
LV) enlargement or systolic functional impairment by
adionuclide ventriculography or echocardiography, accord-
ng to the European Society of Cardiology guidelines (10).
atients with isolated diastolic dysfunction, valvular disease,
yocardial infarction (within 12 weeks), cerebrovascular
ccident (within 12 weeks), or severe renal failure (creati-
ine 220 mol/l) were excluded. To evaluate the EPO
esponse in patients without CHF, we included 15 patients
eferred to our center with complaints of chest pain or
alpitations. Control patients had a mean age of 50.1  4.5
ears and had a normal LV function (left ventricular ejection
raction [LVEF] 0.60), normal renal function, no clinical
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EPO and Survival in Heart Failure July 7, 2004:63–7igns of inflammation, and no evidence of CHF. All
ubjects gave informed consent for the protocol, which was
pproved by the local medical ethics committee. Follow-up
ata were obtained by review of the medical record or by
elephone. The primary end point of the study was all-cause
ortality. No cardiac transplantations were observed in this
opulation.
easurement of brain natriuretic peptide (BNP) and
PO levels. Venous blood samples were taken in the
orning to avoid circadian influences. Plasma was stored at
80°C, and BNP concentrations were determined with an
mmunoradiometric assay (Shionoria, Osaka, Japan).
lasma EPO levels were measured using the IMMULITE
PO assay (DPC, Los Angeles, California), which has been
escribed before (11). The DPC assay consists of a ligand-
Abbreviations and Acronyms
BNP  brain natriuretic peptide
CHF  chronic heart failure
CI  confidence interval
EPO  erythropoietin
GFR  glomerular filtration rate
Hb  hemoglobin
HR  hazard ratio
LV  left ventricular
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
Table 1. Baseline Characteristics
Variables
Total Cohor
(n  74)
Age (yrs) 60.9  1.7
Gender (% male) 73.0
NYHA (%)
Class II 36.5
Class III 32.4
Class IV 31.1
Ischemic etiology (%) 47.3
History of hypertension (%) 40.6
History of diabetes (%) 12.2
LVEF (%) 0.31  0.01
VO2 (ml kg
1 min1) 19.1  0.6
Calculated GFR (ml/min) 76.0  3.5
BNP (pmol/l) 109.9  13.5
Sodium (mmol/l) 137.6  0.3
Erythropoietin levels (mU/ml) 19.4  1.5
Hemoglobin levels (g/dl) 13.9  0.2
Left atrial diameter (mm) 63.6  1.5
LV end-systolic diameter (mm) 49.0  1
LV end-diastolic diameter (mm) 60  1
Medication (% use)
ACE inhibitor 81.1
Beta-blocker 67.6
Diuretics 63.5
Aldosterone antagonist 27.0
Nitrates 18.9
Digoxin 27.0
p value  survivors vs. nonsurvivors.
BNP  brain natriuretic peptide; GFR  glomerular filtrfraction; NYHA  New York Heart Association; VO2  oxygenabeled monoclonal anti-EPO capture antibody, an alkaline
hosphatase-labeled polyclonal conjugate antibody, and
olid-phase anti-ligand– coated polystyrene beads. The
mount of plasma EPO was quantified by chemilumines-
ent measurement in a luminometer. The assay showed an
ntra-assay variability of 1%. The impact of age and
ender on plasma EPO levels was limited and not
ignificant.
enal function. The glomerular filtration rate (GFR) is a
tandard indicator of renal function. Under steady-state
onditions, GFR is estimated from serum creatinine using a
ormula that accounts for the influence of age and body
eight on creatinine production GFR (the Cockroft Gault
quation) (12): [140  age in years)  (body weight in
g)]/(72 serum creatinine in mg/dl). In women, the value
s multiplied by 0.85. This formula is validated and used in
everal studies of CHF and renal function (13,14).
tatistics. Data are given as mean SEM and as frequencies
or categorical variables. We included the following risk factors
n our analysis: gender, age, history of hypertension, history of
iabetes, etiology of the CHF, LV end-diastolic dimension,
alculated GFR, sodium levels, concomitant medication, and
everity of CHF assessed by BNP levels, LVEF, and VO2. The
aplan-Meier method was used to study the influence of
everal baseline clinical and biochemical variables on survival in
he study population. The variables with p  0.05 in the
nivariate analysis were used in the multivariate analyses with
Survivors
(n  52)
Nonsurvivors
(n  22) p Value
59.3  2.0 64.5  3.4 0.15
78.9 59.1 0.08
0.001
48.1 9.1
36.5 22.7
15.4 68.2
46.2 50.0 0.76
36.7 50.0 0.31
11.5 13.6 0.80
0.33  0.02 0.26  0.02 0.035
20.4  0.7 16.1  1.0 0.001
79.5  4.0 67.0  6.8 0.10
80.6  12.9 179.1  29.3 0.002
137.8  0.4 137.4  0.7 0.58
16.8  1.3 25.8  3.8 0.033
14.2  0.2 13.3  0.2 0.013
62.7  1.7 65.6  2.8 0.36
47.0  2 53.0  2 0.027
59.0  1 62.0  2 0.28
71.2 90.9 0.16
71.2 59.1 0.21
53.8 86.4 0.009
24.1 39.1 0.24
13.5 31.8 0.07
23.1 36.4 0.24
ate; LV  left ventricular; LVEF  left ventricular ejectiont
ation r
consumption.
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July 7, 2004:63–7 EPO and Survival in Heart Failurehe use of the Cox backward Wald regression analysis. Hazard
atios (HR) with 95% confidence intervals (CI) demonstrate
he risk of death. Pearson and Spearman correlation coeffi-
ients were calculated to determine which clinical and bio-
hemical variable had an univariate correlation with log(EPO).
ll reported probability values were two-tailed, and a p value
0.05 was considered statistically significant. For all statistical
nalysis, SPSS version 11.0 (SPSS Inc., Chicago, Illinois) was
sed.
ESULTS
atient characteristics. The cohort was 80% male, and age
anged from 26 to 90 years. The New York Heart Associ-
tion (NYHA) functional class II, III, and IV comprised
7%, 32%, and 31%, respectively. Other baseline character-
stics are given in Table 1. Of the 74 patients, 22 (30%) died
fter 16 to 1,728 days (mean, 621 days), 77.8% of them had
cardiovascular cause of death. Mean follow-up period of
he 52 survivors was 1,100 days (range, 844 to 1,934 days;
edian, 987 days).
b and EPO levels. Mean Hb levels were 13.9 g/dl
range, 10.6 to 17.6 g/dl; median, 13.8 g/dl). When we used
he generally accepted definition of the World Health
rganization (hemoglobin 12 g/dl for women, 13 g/dl
or men), we found that 24.3% of the CHF patients were
nemic. Non-survivors had lower Hb levels (p  0.05) and
igher plasma EPO levels than survivors (p  0.05). When
og(EPO) was plotted as a function of Hb, only a modest
nverse correlation (r2  0.08, p  0.02) was observed in
HF patients (Fig. 1a). To compare the EPO response in
on-CHF patients, we obtained blood samples from 15
ontrol patients. Interestingly, we found a clear, significant
nverse correlation between log(EPO) and Hb in the control
atients (r2  0.44, p  0.007) (Fig. 1b).
igure 1. (a) Correlation between logarithm (log) (erythropoietin [EPO]
etween log (EPO) and hemoglobin in the control patients.Furthermore, a modest but statistically significant corre- wation was observed between plasma EPO levels and the
everity of CHF, assessed by BNP levels (r2  0.14, p 
.001), NYHA functional class (r2  0.09, p  0.01), and
O2 (r
2  0.09, p  0.01). There was no significant
orrelation between EPO levels and LV end-diastolic di-
ension and LVEF (r2  0.003 and r2  0.04, respec-
ively). Use of medication, including angiotensin-converting
nzyme inhibitors, beta-blockers, and diuretics was not
ignificantly correlated to Hb or EPO levels.
elationship of Hb and EPO with mortality. The
aplan-Meier survival curve clearly demonstrates increased
ortality in patients with anemia, HR 3.28 (95% CI, 1.31
o 8.18; p  0.01) (Fig. 2). Patients with anemia had a
wo-year mortality rate of 33%, compared with 14% for
on-anemic patients. Furthermore, also elevated EPO levels
22.6 mU/ml) are associated with an impaired outcome,
R 2.6 (95% CI, 1.05 to 6.44; p 0.04) (Fig. 3). Two-year
hemoglobin in the chronic heart failure (CHF) cohort. (b) Correlation
igure 2. Kaplan-Meier survival curve for congestive heart failure patients) andith and without anemia.
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EPO and Survival in Heart Failure July 7, 2004:63–7ortality rates were 32% in those with high EPO levels
22.6 mU/ml), compared with 16% for those with low
PO levels (22.6 mU/ml). After adjustment for possible
onfounders, both Hb and EPO levels remained indepen-
ently associated with an increased mortality (Table 2).
ISCUSSION
his is the first study to examine the prognostic value of
PO levels in CHF patients. Our findings demonstrate that
ncreased plasma EPO levels predict an impaired medium-
o longer-term survival in patients with CHF. Furthermore,
s previously described, lower Hb levels were also associated
ith increased mortality (2). However, EPO and Hb were
oth independent prognostic markers. When the correlation
etween EPO and Hb was further studied in CHF patients
nd compared with controls, we observed an inadequate
ncrease in EPO levels relative to the hemoglobin levels.
We found that 24% of the CHF patients were anemic,
ccording to World Health Organization criteria, and Hb
evels were an independent predictor of all-cause mortality.
hese findings are well comparable with others studies,
hich show that anemia is associated with an impaired
urvival in patients with CHF (3,5,15). A recent study of
orwich et al. (2) also showed that anemia was common in
atients with advanced heart failure (NYHA functional
lass III and IV) and that patients with NYHA functional
igure 3. Kaplan-Meier survival curve for the congestive heart failure
ohort by erythropoietin (EPO) level.
Table 2. Univariate and Multivariate Predictor
Variables
Univari
HR CI
LVEF (%) 0.960 0.920–1.
BNP (pmol/l) 1.006 1.003–1.
Hb (g/dl) 0.463 0.278–0.
EPO (mU/ml) 1.042 1.015–1.
Age (yrs) 1.025 0.994–1.
Calculated GFR (ml/min) 0.984 0.965–1.
BNP  brain natriuretic peptide; CI  confidence interval;
LVEF  left ventricular ejection fraction.lass IV were more likely to have lower Hb levels. They also
howed that Hb levels 12.3 g/dl were associated with an
mpaired survival in patients with advanced CHF. However,
he prognostic value of Hb levels in new cases of heart
ailure seems to be limited (16). None of these studies
ssessed the role of endogenous EPO levels in CHF
atients.
We observed that elevated plasma EPO levels were
ssociated with severity of CHF. This finding has previously
een reported by two other groups (8,9). However, we are
he first to show that elevated EPO levels are a prognostic
arker for impaired survival in the CHF population.
urthermore, elevated plasma EPO was a risk factor inde-
endent of Hb levels.
To further elucidate the effect of EPO on Hb levels in
HF patients, we correlated log(EPO) to Hb levels. Inter-
stingly, we found only a very modest inverse correlation
etween log(EPO) and Hb levels in CHF patients, while
here was a clear correlation in the control group. These
ndings may indicate a blunted EPO response relative to
he Hb levels. This mechanism has already been proposed
y others, who suggest that resistance to EPO in the bone
arrow may explain the anemia observed in CHF patients
17).
From the modest correlation between EPO and Hb in
HF patients, we hypothesize that sensitivity to EPO may
e insufficient in CHF patients. Therefore, one might
ssume beneficial effects of EPO treatment in CHF patients
18). Several studies already indicated the positive effects of
PO treatment in CHF patients (4,19,20). A study by
ilverberg (19) showed that the treatment of anemia in
atients with severe CHF, with EPO and intravenous iron,
mproved cardiac function and quality of life, and markedly
educed hospitalization. Another group observed that EPO
reatment in NYHA functional class III to IV patients
nhanced exercise capacity and also improved quality of life
20). These studies showed that EPO treatment is both safe
nd beneficial in anemic CHF patients.
The main limitation of this study was its relatively small
ize (74 patients, 22 events). Furthermore, we did not
easure cytokine levels, which may influence the effect of
PO on Hb levels. We measured EPO and Hb levels on a
ingle point and, thus, can only speculate on its importance
ver time. Because of these limitations, we regard our study
ll-Cause Mortality
Multivariate
p HR CI p
0.059 — — —
0.001 — — —
0.003 0.408 0.219–0.759 0.005
0.002 1.034 1.004–1.064 0.026
0.110 1.031 0.999–1.065 0.056
0.096 — — —
 erythropoietin; Hb  hemoglobin; HR  hazard ratio;s of A
ate
001
009
773
070
056
003
EPO
m
fi
l
s
A
T
a
R
H
p
R
1
1
1
1
1
1
1
1
1
1
2
67JACC Vol. 44, No. 1, 2004 van der Meer et al.
July 7, 2004:63–7 EPO and Survival in Heart Failureainly as a hypothesis-generating study. Nevertheless, our
ndings suggest that lower Hb levels and elevated EPO
evels are both independently associated with an impaired
urvival in CHF patients.
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